Journal of Cutaneous Medicine & Surgery

, Volume 8, Supplement 3, pp 22–31 | Cite as

Role of Topical Therapies in the Management of Cutaneous Disease

  • Robert SkinnerEmail author


Within the last decade, healthcare providers have had a larger selection of effective novel topical immunomodulatory agents to treat many dermatologic conditions. Novel mechanisms of action of newer topical agents have facilitated differentiation from well-established topical agents such as corticosteroids and 5-fluorouracil. Further, because of a growing understanding of the immune mechanisms within the skin, the opportunity has arisen to use the body’s immune system to effectively treat many dermatologic conditions, such as condyloma acuminata, actinic keratosis, basal cell carcinoma, and atopic dermatitis, while maintaining a favorable safety profile. Imiquimod 5% cream, an immune response modifier, is safe and effective in the treatment of condyloma acuminata, actinic keratosis, and primary superficial basal cell carcinoma (sBCC). Pimecrolimus cream 1% and tacrolimus ointment (0.1% and 0.03%) are safe and effective in the treatment of atopic dermatitis. This review highlights newer data on approved and investigational indications for these topical immunomodulatory agents.


Tacrolimus Atopic Dermatitis Imiquimod Actinic Keratosis Pimecrolimus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Smith, ES, Feldman, SR, Fleischer, AB,Jr,  et al. 1998Characteristics of office-based visits for skin cancer. Dermatologists have more experience than other physicians in managing malignant and premalignant skin conditionsDermatol Surg24981985CrossRefPubMedGoogle Scholar
  2. 2.
    Bruner, CR, Feldman, SR, Ventrapragada, M,  et al. 2003A systematic review of adverse effects associated with topical treatments for psoriasisDermatol Online J92PubMedGoogle Scholar
  3. 3.
    Levin, C, Maibach, HI 2002Topical corticosteroid-induced adrenocortical insufficiency: clinical implicationsAm J Clin Dermatol3141147PubMedGoogle Scholar
  4. 4.
    Queille, C, Pommarede, R, Saurat, JH. 1984Efficacy versus systemic effects of six topical steroids in the treatment of atopic dermatitis of childhoodPediatr Dermatol1246253PubMedGoogle Scholar
  5. 5.
    Miller, RL, Gerster, JF, Owens, ML,  et al. 1999Imiquimod applied topically: a novel immune response modifier and new class of drugInt J Immunopharmacol21114CrossRefPubMedGoogle Scholar
  6. 6.
    Hemmi, H, Kaisho, T, Takeuchi, O,  et al. 2002Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathwayNat Immunol3196200CrossRefPubMedGoogle Scholar
  7. 7.
    Takeda, K, Akira, S 2001Roles of Toll-like receptors in innate immune responsesGenes Cells6733742CrossRefPubMedGoogle Scholar
  8. 8.
    Vasselon, T, Detmers, PA 2002Toll receptors: a central element in innate immune responsesInfect Immun7010331041CrossRefPubMedGoogle Scholar
  9. 9.
    Imbertson, LM, Beaurline, JM, Couture, AM,  et al. 1998Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463J Invest Dermatol110734739CrossRefPubMedGoogle Scholar
  10. 10.
    Arany, I, Tyring, SK, Stanley, MA,  et al. 1999Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%Antiviral Res435563CrossRefPubMedGoogle Scholar
  11. 11.
    Tyring, SK, Arany, I, Stanley, MA,  et al. 1998A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimodJ Infect Dis178551555PubMedGoogle Scholar
  12. 12.
    Doxsee, CL, Riter, TR, Reiter, MJ,  et al. 2003The immune response modifier and Toll-like receptor 7 agonist S-27609 selectively induces IL-12 and TNF-alpha production in CD11c+CD11b+CD8- dendritic cellsJ Immunol17111561163PubMedGoogle Scholar
  13. 13.
    Nair, S, McLaughlin, C, Weizer, A,  et al. 2003Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturationJ Immunol17162756282PubMedGoogle Scholar
  14. 14.
    Schon, M, Bong, AB, Drewniok, C,  et al. 2003Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimodJ Natl Cancer Inst9511381149PubMedCrossRefGoogle Scholar
  15. 15.
    American Social Health Association and the Kaiser Family Foundation. Sexually Transmitted Diseases in America: How Many Cases and at What Cost? December 1998. Available at: Accessed July 22, 2003
  16. 16.
    Edwards, L, Ferenczy, A, Eron, L,  et al. 1998Self-administered topical 5% imiquimod cream for external anogenital wartsArch Dermatol1342530CrossRefPubMedGoogle Scholar
  17. 17.
    Bayerl, C, Feller, G, Goerdt, S 2003Experience in treating molluscum contagiosum in children with imiquimod 5% creamBr J Dermatol1492528CrossRefPubMedGoogle Scholar
  18. 18.
    Hengge, UR, Esser, S, Schultewolter, T,  et al. 2000Self-administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosumBr J Dermatol14310261031CrossRefPubMedGoogle Scholar
  19. 19.
    Barba, AR, Kapoor, S, Berman, B 2001An open label safety study of topical imiquimod 5% cream in the treatment of molluscum contagiosum in childrenDermatol Online J720PubMedGoogle Scholar
  20. 20.
    Stockfleth, E, Meyer, T, Benninghoff, B,  et al. 2002A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratosesArch Dermatol13814981502CrossRefPubMedGoogle Scholar
  21. 21.
    Lebwohl, M, Dinehart, S, Whiting, D,  et al. 2004Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trialsJ Am Acad Dermatol50714721CrossRefPubMedGoogle Scholar
  22. 22.
    Geisse, JK, Rich, P, Pandya, A,  et al. 2002Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled studyJ Am Acad Dermatol47390398CrossRefPubMedGoogle Scholar
  23. 23.
    Geisse, J, Caro, I, Lindholm, J,  et al. 2004Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studiesJ Am Acad Dermatol50722733CrossRefPubMedGoogle Scholar
  24. 24.
    Shumack, S, Robinson, J, Kossard, S,  et al. 2002Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimensArch Dermatol13811651171CrossRefPubMedGoogle Scholar
  25. 25.
    Mackenzie-Wood, A, Kossard, S, de Launey, J,  et al. 2001Imiquimod 5% cream in the treatment of Bowen’s diseaseJ Am Acad Dermatol44462470CrossRefPubMedGoogle Scholar
  26. 26.
    Naylor, MF, Crowson, N, Kuwahara, R,  et al. 2003Treatment of lentigo maligna with topical imiquimodBr J Dermatol149 (suppl 66)6670Google Scholar
  27. 27.
    Becker, TM, Blount, JH, Douglas, J,  et al. 1986Trends in molluscum contagiosum in the United States, 1966-1983Sex Transm Dis138892PubMedCrossRefGoogle Scholar
  28. 28.
    Jeffes, EW,3rd, Tang, EH 2000Actinic keratosis. Current treatment optionsAm J Clin Dermatol1167179PubMedGoogle Scholar
  29. 29.
    Frost, CA, Green, AC 1994Epidemiology of solar keratosesBr J Dermatol131455464PubMedCrossRefGoogle Scholar
  30. 30.
    American Cancer Society. 2003Cancer Facts & Figures 2003American Cancer SocietyAtlanta GAGoogle Scholar
  31. 31.
    Iftner, A, Klug, SJ, Garbe, C,  et al. 2003The prevalence of human papillomavirus genotypes in nonmelanoma skin cancers of nonimmunosuppressed individuals identifies high-risk genital types as possible risk factorsCancer Res6375157519PubMedGoogle Scholar
  32. 32.
    Arlette, JP 2003Treatment of Bowen’s disease and erythroplasia of QueyratBr J Dermatol149 (suppl 66)4349CrossRefGoogle Scholar
  33. 33.
    Nouri, K, O’Connell, C, Rivas, MP 2003Imiquimod for the treatment of Bowen’s disease and invasive squamous cell carcinomaJ Drugs Dermatol2669673PubMedGoogle Scholar
  34. 34.
    Schroeder, TL, Sengelmann, RD 2002Squamous cell carcinoma in situ of the penis successfully treated with imiquimod 5% creamJ Am Acad Dermatol46545548CrossRefPubMedGoogle Scholar
  35. 35.
    Albino, AP, Reed, JA, McNutt, NS (1997) “Malignant melanoma” In: DeVita, VT, Jr, Hellman, S, Rosenberg, Sa (eds), Cancer: Principles & Practice of Oncology, 5, Lippincott-Raven Publishers, Philadelphia, PA, pp 1935–1955Google Scholar
  36. 36.
    Grassberger, M, Baumruker, T, Enz, A,  et al. 1999A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacologyBr J Dermatol141264273CrossRefPubMedGoogle Scholar
  37. 37.
    Zuberbier, T, Chong, SU, Grunow, K,  et al. 2001The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophilsJ Allergy Clin Immunol108275280CrossRefPubMedGoogle Scholar
  38. 38.
    Eichenfield, LF, Lucky, AW, Boguniewicz, M,  et al. 2002Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescentsJ Am Acad Dermatol46495504CrossRefPubMedGoogle Scholar
  39. 39.
    Paller, A, Eichenfield, LF, Leung, DY,  et al. 2001A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patientsJ Am Acad Dermatol44S47S57CrossRefPubMedGoogle Scholar
  40. 40.
    Kapp, A, Papp, K, Bingham, A,  et al. 2002Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drugJ Allergy Clin Immunol110277284CrossRefPubMedGoogle Scholar
  41. 41.
    Meingassner, JG, Fahrngruber, H, Bavandi, A 2003Pimecrolimus inhibits the elicitation phase but does not suppress the sensitization phase in murine contact hypersensitivity, in contrast to tacrolimus and cyclosporine AJ Invest Dermatol1217780CrossRefPubMedGoogle Scholar
  42. 42.
    Amrol, D, Keitel, D, Hagaman, D,  et al. 2003Topical pimecrolimus in the treatment of human allergic contact dermatitisAnn Allergy Asthma Immunol91563566PubMedCrossRefGoogle Scholar
  43. 43.
    Brownell, I, Quan, LT, Hsu, S 2003Topical pimecrolimus in the treatment of seborrheic dermatitisDermatol Online J913PubMedGoogle Scholar
  44. 44.
    Crutchfield, CE,3rd 2002Pimecrolimus: a new treatment for seborrheic dermatitisCutis70207208PubMedGoogle Scholar
  45. 45.
    Mayoral, FA, Gonzalez, C, Shah, NS,  et al. 2003Repigmentation of vitiligo with pimecrolimus cream: a case reportDermatology207322323CrossRefPubMedGoogle Scholar
  46. 46.
    Mrowietz, U, Wustlich, S, Hoexter, G,  et al. 2003An experimental ointment formulation of pimecrolimus is effective in psoriasis without occlusionActa Derm Venereol83351353CrossRefPubMedGoogle Scholar
  47. 47.
    Rappersberger, K, Komar, M, Ebelin, ME,  et al. 2002Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well toleratedJ Invest Dermatol119876887CrossRefPubMedGoogle Scholar
  48. 48.
    Reynolds, NJ, Al-Daraji, WI. 2002Calcineurin inhibitors and sirolimus: mechanisms of action and applications in dermatologyClin Exp Dermatol27555561CrossRefPubMedGoogle Scholar
  49. 49.
    Sakuma, S, Higashi, Y, Sato, N,  et al. 2001Tacrolimus suppressed the production of cytokines involved in atopic dermatitis by direct stimulation of human PBMC system. (Comparison with steroids)Int Immunopharmacol112191226CrossRefPubMedGoogle Scholar
  50. 50.
    Sasakawa, T, Higashi, Y, Sakuma, S,  et al. 2004Topical application of FK506 (tacrolimus) ointment inhibits mite antigen-induced dermatitis by local action in NC/Nga miceInt Arch Allergy Immunol1335563CrossRefPubMedGoogle Scholar
  51. 51.
    Hanifin, JM, Ling, MR, Langley, R,  et al. 2001Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacyJ Am Acad Dermatol44S28S38CrossRefPubMedGoogle Scholar
  52. 52.
    Soter, NA, Fleischer, AB,Jr, Webster, GF,  et al. 2001Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safetyJ Am Acad Dermatol44 (suppl)S39S46CrossRefGoogle Scholar
  53. 53.
    Kang, S, Lucky, AW, Pariser, D,  et al. 2001Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in childrenJ Am Acad Dermatol44 (suppl)S58S64CrossRefGoogle Scholar
  54. 54.
    Meshkinpour, A, Sun, J, Weinstein, G 2003An open pilot study using tacrolimus ointment in the treatment of seborrheic dermatitisJ Am Acad Dermatol49145147CrossRefPubMedGoogle Scholar
  55. 55.
    Braza, TJ, DiCarlo, JB, Soon, SL,  et al. 2003Tacrolimus 0.1% ointment for seborrhoeic dermatitis: an open-label pilot studyBr J Dermatol14812421244CrossRefPubMedGoogle Scholar
  56. 56.
    Saripalli, YV, Gadzia, JE, Belsito, DV 2003Tacrolimus ointment 0.1% in the treatment of nickel-induced allergic contact dermatitisJ Am Acad Dermatol49477482CrossRefPubMedGoogle Scholar
  57. 57.
    Assmann, T, Becker-Wegerich, P, Grewe, M,  et al. 2003Tacrolimus ointment for the treatment of vulvar lichen sclerosusJ Am Acad Dermatol48935937CrossRefPubMedGoogle Scholar
  58. 58.
    Bohm, M, Frieling, U, Luger, TA,  et al. 2003Successful treatment of anogenital lichen sclerosus with topical tacrolimusArch Dermatol139922924CrossRefPubMedGoogle Scholar
  59. 59.
    Bamford, JT, Elliott, BA, Haller, IV. 2004Tacrolimus effect on rosaceaJ Am Acad Dermatol50107108CrossRefPubMedGoogle Scholar
  60. 60.
    Bohm, M, Gaubitz, M, Luger, TA,  et al. 2003Topical tacrolimus as a therapeutic adjunct in patients with cutaneous lupus erythematosus. A report of three casesDermatology207381385CrossRefPubMedGoogle Scholar
  61. 61.
    Yoshimasu, T, Ohtani, T, Sakamoto, T,  et al. 2002Topical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatomyositisEur J Dermatol125052PubMedGoogle Scholar
  62. 62.
    Chu, J, Bradley, M, Marinkovich, MP 2003Topical tacrolimus is a useful adjunctive therapy for bullous pemphigoidArch Dermatol139813815CrossRefPubMedGoogle Scholar
  63. 63.
    Ko, MJ, Chu, CY 2003Topical tacrolimus therapy for localized bullous pemphigoidBr J Dermatol14910791081CrossRefPubMedGoogle Scholar
  64. 64.
    Hodgson, TA, Sahni, N, Kaliakatsou, F,  et al. 2003Long-term efficacy and safety of topical tacrolimus in the management of ulcerative/erosive oral lichen planusEur J Dermatol13466470PubMedGoogle Scholar
  65. 65.
    Kaliakatsou, F, Hodgson, TA, Lewsey, JD,  et al. 2002Management of recalcitrant ulcerative oral lichen planus with topical tacrolimusJ Am Acad Dermatol463541CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  1. 1.Department of Medicine, Division of DermatologyUniversity of Tennessee Health Science CenterMemphisUSA
  2. 2.Department of Medicine, Division of DermatologyUniversity of Tennessee Health Science CenterMemphisUSA

Personalised recommendations